Robert A. Floyd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Robert A. Floyd has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Rheal A. Towner
Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, OK
3 shared publications- Charles Stewart
Oklahoma Medical Research Foundation
2 shared publications - Donald L. Ewert
Hough Ear Institute
2 shared publications - Jianzhong Lu
Hough Ear Institute
2 shared publications - Matthew B. West
Hough Ear Institute, Oklahoma City, USA
2 shared publications - Richard D. Kopke
Hough Ear Institute
2 shared publications
Latest Publications
- 28 February 2014
- Published by Springer Nature in Journal of the Association for Research in Otolaryngology
- Vol. 15 (3) , 373-374
Erratum to: Antioxidants Reduce Cellular and Functional Changes Induced by Intense Noise in the Inner Ear and Cochlear Nucleus
- 28 February 2014
- Published by Springer Nature in Journal of the Association for Research in Otolaryngology
- Vol. 15 (3) , 373-374
Erratum to: Antioxidants Reduce Cellular and Functional Changes Induced by Intense Noise in the Inner Ear and Cochlear Nucleus
- 5 February 2014
- Published by Springer Nature in Journal of the Association for Research in Otolaryngology
- Vol. 15 (3) , 353-372
Antioxidants Reduce Cellular and Functional Changes Induced by Intense Noise in the Inner Ear and Cochlear Nucleus
The present study marks the first evaluation of combined application of the antioxidant N-acetylcysteine (NAC) and the free radical spin trap reagent, disodium 2,4-disulfophenyl-N-tert-butylnitrone (HPN-07), as a therapeutic approach for noise-induced hearing loss (NIHL). Pharmacokinetic studies and C-14 tracer experiments demonstrated that both compounds achieve high blood levels within 30 min after i.p injection, with sustained levels of radiolabeled cysteine (released from NAC) in the cochlea, brainstem, and auditory cortex for up to 48 h. Rats exposed to 115 dB octave-band noise (10–20 kHz) for 1 h were treated with combined NAC/HPN-07 beginning 1 h after noise exposure and for two consecutive days. Auditory brainstem responses (ABR) showed that treatment substantially reduced the degree of threshold shift across all test frequencies (2–16 kHz), beginning at 24 h after noise exposure and continuing for up to 21 days. Reduced distortion product otoacoustic emission (DPOAE) level shifts were also detected at 7 and 21 days following noise exposure in treated animals. Noise-induced hair cell (HC) loss, which was localized to the basal half of the cochlea, was reduced in treated animals by 85 and 64 % in the outer and inner HC regions, respectively. Treatment also significantly reduced an increase in c-fos-positive neuronal cells in the cochlear nucleus following noise exposure. However, no detectable spiral ganglion neuron loss was observed after noise exposure. The results reported herein demonstrate that the NAC/HPN-07 combination is a promising pharmacological treatment of NIHL that reduces both temporary and permanent threshold shifts after intense noise exposure and acts to protect cochlear sensory cells, and potentially afferent neurites, from the damaging effects of acoustic trauma. In addition, the drugs were shown to reduce aberrant activation of neurons in the central auditory regions of the brain following noise exposure. It is likely that the protective mechanisms are related to preservation of structural components of the cochlea and blocking the activation of immediate early genes in the auditory centers of the brain.
- 5 February 2014
- Published by Springer Nature in Journal of the Association for Research in Otolaryngology
- Vol. 15 (3) , 353-372
Antioxidants Reduce Cellular and Functional Changes Induced by Intense Noise in the Inner Ear and Cochlear Nucleus
The present study marks the first evaluation of combined application of the antioxidant N-acetylcysteine (NAC) and the free radical spin trap reagent, disodium 2,4-disulfophenyl-N-tert-butylnitrone (HPN-07), as a therapeutic approach for noise-induced hearing loss (NIHL). Pharmacokinetic studies and C-14 tracer experiments demonstrated that both compounds achieve high blood levels within 30 min after i.p injection, with sustained levels of radiolabeled cysteine (released from NAC) in the cochlea, brainstem, and auditory cortex for up to 48 h. Rats exposed to 115 dB octave-band noise (10–20 kHz) for 1 h were treated with combined NAC/HPN-07 beginning 1 h after noise exposure and for two consecutive days. Auditory brainstem responses (ABR) showed that treatment substantially reduced the degree of threshold shift across all test frequencies (2–16 kHz), beginning at 24 h after noise exposure and continuing for up to 21 days. Reduced distortion product otoacoustic emission (DPOAE) level shifts were also detected at 7 and 21 days following noise exposure in treated animals. Noise-induced hair cell (HC) loss, which was localized to the basal half of the cochlea, was reduced in treated animals by 85 and 64 % in the outer and inner HC regions, respectively. Treatment also significantly reduced an increase in c-fos-positive neuronal cells in the cochlear nucleus following noise exposure. However, no detectable spiral ganglion neuron loss was observed after noise exposure. The results reported herein demonstrate that the NAC/HPN-07 combination is a promising pharmacological treatment of NIHL that reduces both temporary and permanent threshold shifts after intense noise exposure and acts to protect cochlear sensory cells, and potentially afferent neurites, from the damaging effects of acoustic trauma. In addition, the drugs were shown to reduce aberrant activation of neurons in the central auditory regions of the brain following noise exposure. It is likely that the protective mechanisms are related to preservation of structural components of the cochlea and blocking the activation of immediate early genes in the auditory centers of the brain.
- 1 September 2011
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 51 (5) , 931-941
Translational research involving oxidative stress and diseases of aging
- 1 September 2011
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 51 (5) , 931-941
Translational research involving oxidative stress and diseases of aging
- 1 May 2011
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 11 (4) , 373-379
Anti-Cancer Activity of Nitrones and Observations on Mechanism of Action
The nitrone compound PBN, α-phenyl-tert-butylnitrone, and closely related nitrones have anti-cancer activity in several experimental cancer models. The three experimental models most extensively studied include A) the rat choline deficiency liver cancer model, B) the rat C6 glioma model and C) the mouse APCMin/+ colon cancer model. The two PBN-nitrones mostly studied are PBN and a PBN derivative 2,4-disulfophenyl-tert-butylnitrone, referred as OKN-007. OKN-007 is a proprietary compound that has had extensive commercial development (designated as NXY-059) for another indication, acute ischemic stroke, and after extensive clinical studies was shown to lack efficacy for this indication but was shown to be very safe for human use. This compound administered orally in the rat glioma model has potent activity in treating fully formed gliomas. In this report observations made on the PBN-nitrones in experimental cancer models will be summarized. In addition the experimental results will be discussed in the general framework of the properties of the compounds with a view to try to understand the mechanistic basis of how the PBN-nitrones act as anti-cancer agents. Possible mechanisms related to the suppression of NO production, S-nitrosylation of critical proteins and inhibition of NF-κB activation are discussed.
- 1 May 2011
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 11 (4) , 373-379
Anti-Cancer Activity of Nitrones and Observations on Mechanism of Action
The nitrone compound PBN, α-phenyl-tert-butylnitrone, and closely related nitrones have anti-cancer activity in several experimental cancer models. The three experimental models most extensively studied include A) the rat choline deficiency liver cancer model, B) the rat C6 glioma model and C) the mouse APCMin/+ colon cancer model. The two PBN-nitrones mostly studied are PBN and a PBN derivative 2,4-disulfophenyl-tert-butylnitrone, referred as OKN-007. OKN-007 is a proprietary compound that has had extensive commercial development (designated as NXY-059) for another indication, acute ischemic stroke, and after extensive clinical studies was shown to lack efficacy for this indication but was shown to be very safe for human use. This compound administered orally in the rat glioma model has potent activity in treating fully formed gliomas. In this report observations made on the PBN-nitrones in experimental cancer models will be summarized. In addition the experimental results will be discussed in the general framework of the properties of the compounds with a view to try to understand the mechanistic basis of how the PBN-nitrones act as anti-cancer agents. Possible mechanisms related to the suppression of NO production, S-nitrosylation of critical proteins and inhibition of NF-κB activation are discussed.
- 3 November 2009
- Published by Taylor & Francis in Free Radical Research
- Vol. 44 (1) , 108-117
Anti-cancer activity of nitrones in theApcMin/+model of colorectal cancer
The nitrones of α-phenyl-tert-butyl nitrone (PBN) and 4-hydroxyl-PBN (4-OH-PBN) that have anti-cancer activity in models of liver cancer and glioblastomas were tested in the ApcMin/+ mouse model. Mice were administered PBN and 4-OH-PBN in drinking water and intestinal tumour size and number assessed after 3–4 months. Throughout the experiment, contrast-enhanced magnetic resonance imaging (MRI) was used to monitor colon tumours. MRI data showed a time-dependent significant increase in total colonic signal intensity in sham-treated mice, but a significant decrease for PBN-treated mice and slight decrease for 4-OHPBN treated mice, probably due to the limited water solubility of 4-OH-PBN. Final pathological and percentage survival data agreed with the MRI data. PBN had little effect on oxaliplatin-mediated killing of HCT116 colon cancer cells and caused only a slight decrease in the amount of active fraction caspase 3 in oxaliplatin-treated cells. PBN has significant anti-cancer activity in this model of intestinal neoplasia.
- 3 November 2009
- Published by Taylor & Francis in Free Radical Research
- Vol. 44 (1) , 108-117
Anti-cancer activity of nitrones in theApcMin/+model of colorectal cancer
The nitrones of α-phenyl-tert-butyl nitrone (PBN) and 4-hydroxyl-PBN (4-OH-PBN) that have anti-cancer activity in models of liver cancer and glioblastomas were tested in the ApcMin/+ mouse model. Mice were administered PBN and 4-OH-PBN in drinking water and intestinal tumour size and number assessed after 3–4 months. Throughout the experiment, contrast-enhanced magnetic resonance imaging (MRI) was used to monitor colon tumours. MRI data showed a time-dependent significant increase in total colonic signal intensity in sham-treated mice, but a significant decrease for PBN-treated mice and slight decrease for 4-OHPBN treated mice, probably due to the limited water solubility of 4-OH-PBN. Final pathological and percentage survival data agreed with the MRI data. PBN had little effect on oxaliplatin-mediated killing of HCT116 colon cancer cells and caused only a slight decrease in the amount of active fraction caspase 3 in oxaliplatin-treated cells. PBN has significant anti-cancer activity in this model of intestinal neoplasia.
- 1 April 2009
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 46 (8) , 1004-1013
Serendipitous findings while researching oxygen free radicals
- 1 April 2009
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 46 (8) , 1004-1013
Serendipitous findings while researching oxygen free radicals
- 1 November 2008
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 45 (10) , 1361-1374
Nitrones as therapeutics
- 1 November 2008
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 45 (10) , 1361-1374
Nitrones as therapeutics
- 20 July 1999
- Published by Wiley in Journal of High Resolution Chromatography
- Vol. 22 (8) , 429-437
Determination of Biological Oxidative Stress Using High Performance Liquid Chromatography with Electrochemical Detection (HPLC-ECD)
- 20 July 1999
- Published by Wiley in Journal of High Resolution Chromatography
- Vol. 22 (8) , 429-437
Determination of Biological Oxidative Stress Using High Performance Liquid Chromatography with Electrochemical Detection (HPLC-ECD)